ArticleMicrobial cell factories2025
Evaluation of the antibacterial and antibiofilm effect of mycosynthesized silver and selenium nanoparticles and their synergistic effect with antibiotics on nosocomial bacteria.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Green synthesis of selenium nanoparticles using Bacillus sp. strain STG-83: optimization, characterization, and prospects for cancer radiosensitization.Scientific reports · 2026Article
- Biosynthesis and antibacterial activity of selenium nanoparticles using Pseudomonas aeruginosa and Bacillus pumilus RMO6.Discover nano · 2026Article
- Selenium nanoparticles: Eco-friendly synthesis, biological activities and biomedical applications - A comprehensive review.Materials today. Bio · 2026Review
- Optimization of probiotic-mediated selenium nanoparticles for superior antibacterial action against methicillin-resistant Staphylococcus aureus.Discover nano · 2026Article
- Biogenic Silver-Selenium nanocomposite with anticancer activity and potent efficacy against vancomycin-resistant Staphylococcus aureus.PloS one · 2026Article
- From Bioactive Selenium Nanoparticles to Multifunctional Dermatological Platforms: Mechanism-Guided Design and Translational Challenges.International journal of nanomedicine · 2026Review
- Nanoparticle-Based Drug Delivery Systems: Current Advances and Future Directions.Current drug targets · 2026Review
- Harnessing biogenic nanoparticles for combating antibiotic resistance: green synthesis, mechanistic insights, and biotechnological applications.Frontiers in bioengineering and biotechnology · 2026Review
- Green-Synthesized Nanomaterials from Edible and Medicinal Mushrooms: A Sustainable Strategy Against Antimicrobial Resistance.Pharmaceutics · 2025Review
- Surface modifications of superparamagnetic iron oxide nanoparticles with citric acid, selenium, and silver combining with polymer blend as antibacterial agent.Discover nano · 2025Article
- Anti-Rickettsial Activity of Chitosan, Selenium, and Silver Nanoparticles: Efficacy in Vero Cells.Pathogens (Basel, Switzerland) · 2025Article
- Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,Pharmaceuticals (Basel, Switzerland) · 2025Review
- Colistin-Conjugated Selenium Nanoparticles: A Dual-Action Strategy Against Drug-Resistant Infections and Cancer.Pharmaceutics · 2025Article
- Bacterial responses toRSC advances · 2025Article
- Biosynthesis and Characterization of Selenium Nanoparticles byIranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe healthcare sector faces a growing threat from the rise of highly resistant microorganisms, particularly Methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa). Facing the challenge of antibiotic resistance, nanoparticles have surfaced as promising substitutes for antimicrobial therapy. Recent studies showcase the effectiveness of various fungi species in nanoparticle synthesis. Mycosynthesized silver nanoparticles (AgNPs) and selenium nanoparticles (SeNPs) using Aspergillus carneus MAK 259 has been investigated and demonstrate antibacterial, antibiofilm and synergistic activities against (MRSA) and (MDR P. aeruginosa).
resultsIn the current research, silver nanoparticles (AgNPs) and selenium nanoparticles (SeNPs) were produced extracellularly using A. carneus MAK 259 culture supernatants. Colour change, an initial evaluation of the production of AgNPs and SeNPs. Then, UV absorption peaks at 410 nm and 260 nm confirmed the production of AgNPs and SeNPs, respectively. AgNPs and SeNPs were dispersed consistently between 5‒26 nm and 20-77 nm in size, respectively using TEM. FT-IR analysis was used for assessing proteins bound to the produced nanoparticles. The crystallinity and stability of AgNPs and SeNPs was confirmed using X-ray diffraction analysis and zeta potential measurements, respectively. Antibacterial, antibiofilm and synergistic effects of both (NPs) with antibiotics against MRSA and MDR P. aeruginosa were tested by Agar well diffusion, tissue culture plate and disc diffusion method respectively. Both (NPs) inhibited the growth of P. aeruginosa more than S. aureus. But, SeNPs was stronger. AgNPs had stronger antibiofilm effect especially on biofilms producing S. aureus. as regard synergestic effects, Both (NPs) had higher synergestic effects in combination with cell wall inhibiting antibiotics against P. aeuroginosa While, on S. aureus with antibiotics that inhibit protein synthesis and affect metabolic pathways.
conclusionsOur study demonstrated that the mycosynthesized SeNPs had remarkable antibacterial effect while, mycosynthesized AgNPs exhibited a considerable antibiofilm effect. Both NPs exhibited higher synergistic effect with antibiotics with different modes of action. This approach could potentially enhance the efficacy of existing antibiotics, providing a new weapon against drug-resistant bacteria where the described silver and selenium nanoparticles play a pivotal role in revolutionizing healthcare practices, offering innovative solutions to combat antibiotic resistance, and contributing to the development of advanced medical technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.